The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2
Open accessAbstract
This study investigates the apoptotic activity of the cyclooxygenase-2 (COX-2) inhibitor celecoxib in prostate carcinoma cells. COX-2 is constitutively expressed in androgen-responsive LNCaP and androgen-nonresponsive PC-3 cells. Exposure of these cells to celecoxib induces characteristic features of apoptosis, including morphological changes, DNA laddering, and caspase-3 activation, whereas piroxicam, a COX-1-specific inhibitor, displays no appreciable effect on either cancer cell line even after prolonged exposure. Moreover, the potency of celecoxib in apoptosis induction is significantly higher than that of other COX-2 inhibitors examined despite the observation that these inhibitors exhibit similar IC(50) in COX-2 inhibition. It is noteworthy that normal human prostate epithelial cells, expressing a marginally detectable level of COX-2, are insensitive to the induction of apoptosis by celecoxib. These data suggest a correlation between COX-2 expression and sensitivity to the apoptotic effect of the COX-2 inhibitor. In an effort to delineate the underlying mechanism, we examined the effect of celecoxib on the expression of Bcl-2 as well as the activation of the key anti-apoptotic kinase Akt. In contrast to an earlier report that attributed the apoptotic activity of NS398 in LNCaP cells to Bcl-2 down-regulation, we provide evidence that the induction of apoptosis by celecoxib in LNCaP and PC-3 cells is independent of Bcl-2. First, treatment with celecoxib does not alter the cellular Bcl-2 level in both cell lines. Second, enforced Bcl-2 expression in PC-3 cells does not confer protection against the induction of apoptosis by celecoxib. Our data show that celecoxib treatment blocks the phosphorylation of Akt. This correlation is supported by studies showing that overexpression of constitutively active Akt protects PC-3 cells from celecoxib-induced apoptosis. Nevertheless, how celecoxib down-regulates Akt is not clear because the drug does not adversely affect phosphoinositide 3-kinase activity in vivo and okadaic acid, a protein phosphatase 2A inhibitor, cannot rescue the inhibition. In summary, our data demonstrate that inhibition of Akt activation may play a crucial role in the induction of apoptosis by celecoxib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thornberry, N. A., & Lazebnik, Y. (1998) · Science · doi:10.1126/science.281.5381.1312 · Cited by 6,887
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., & Taketo, M. M. (1996) · Cell · doi:10.1016/s0092-8674(00)81988-1 · Cited by 2,366
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Franke, T. F., Yang, S.-I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., & Tsichlis, P. N. (1995) · Cell · doi:10.1016/0092-8674(95)90534-0 · Cited by 2,006
Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2
Smith, W. L., Garavito, R. M., & DeWitt, D. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33157 · Cited by 1,978
Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797
Aspirin Use and Reduced Risk of Fatal Colon Cancer
Thun, M. J., Namboodiri, M. M., & Heath, C. W. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252301 · Cited by 1,673
Expression of cyclooxygenase-1 and -2 in human colorectal cancer.
Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., & Hla, T. (1995) · PubMed · Cited by 1,126
Aspirin and the Risk of Colorectal Cancer in Women
Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331001 · Cited by 1,090
McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C. J., Chung, L. W. K., Hsieh, J., Tu, S., & Campbell, M. L. (1992) · PubMed · Cited by 1,049
Aspirin use and risk of fatal cancer.
Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., & Heath, C. W. (1993) · PubMed · Cited by 870
Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.
Kargman, S., O’Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., & Jothy, S. (1995) · PubMed · Cited by 824
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1529 · Cited by 757
Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study
Schreinemachers, D. M., & Everson, R. B. (1994) · Epidemiology · doi:10.1097/00001648-199403000-00003 · Cited by 736
Cyclooxygenase-2 expression in human esophageal carcinoma.
Zimmermann, K. C., Sarbia, M., Weber, A., Borchard, F., Gabbert, H. E., & Schrör, K. (1999) · PubMed · Cited by 664
Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in Human Breast Cancer
Hwang, D., Byrne, J., Scollard, D., & Levine, E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.6.455 · Cited by 651
Hanif, R., Pittas, A., Feng, Y., Koutsos, M. I., Qiao, L., Staiano-Coico, L., Shiff, S. I., & Rigas, B. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00181-5 · Cited by 608
Colombel, M. C., Symmans, W. F., de Medina, S. G. D., O’Toole, K., Chopin, D. K., Benson, M. C., Olsson, C. A., Korsmeyer, S. J., & Buttyan, R. (1993) · PubMed · Cited by 591
Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
Chan, T. A., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.681 · Cited by 579
Liu, X., Yao, S., Kirschenbaum, A. M., & Levine, A. C. (1998) · Cancer Research · Cited by 466
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.
Piazza, G. A., Rahm, A. L. K., Krutzsch, M. F., Sperl, G. J., Paranka, N. S., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., & Pamukcu, R. (1995) · PubMed · Cited by 465
Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., Zimmerman, G. A., White, R. L., & Prescott, S. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4816 · Cited by 449
Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells.
Subbaramaiah, K., TELANG, N. T., Ramonetti, J. T., Araki, R., DeVito, B., Weksler, B. B., & Dannenberg, A. J. (1996) · PubMed · Cited by 418
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1609 · Cited by 399
Zhou, H., Summers, S. A., Birnbaum, M. J., & Pittman, R. N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16568 · Cited by 347
Nonsteroidal Antiinflammatory Drugs and Breast Cancer
Harris, R. E., Namboodiri, K. K., & Farrar, W. B. (1996) · Epidemiology · doi:10.1097/00001648-199603000-00017 · Cited by 345
Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells
Tjandrawinata, R., Dahiya, R., & Hughes-Fulford, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.192 · Cited by 219
Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
Thompson, H. J., Jiang, C., Lü, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R., & Ahnen, D. J. (1997) · PubMed · Cited by 209
Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress
Zundel, W., & Giaccia, A. (1998) · Genes & Development · doi:10.1101/gad.12.13.1941 · Cited by 209
McDonnel, T. J., Navone, N. M., Troncoso, P., Pisters, L. L., Conti, C. J., von Eschenbach, A. C., Brisbay, S. M., & Logothetis, C. J. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)65204-2 · Cited by 137
Kara, A., Yoshimi, N., Niwa, M., Ino, N., & Mori, H. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00424.x · Cited by 109
Tumorigenic Transformation of Immortalized ECV Endothelial Cells by Cyclooxygenase-1 Overexpression
Narko, K., Ristimaki, A. P., MacPhee, M. J., Smith, E., Haudenschild, C. C., & Hla, T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21455 · Cited by 97
The Effect of Selective Cyclooxygenase Inhibitors on Intestinal Epithelial Cell Mitogenesis
Erickson, B. A., Longo, W. E., Panesar, N. K., Mazuski, J. E., & Kaminski, D. L. (1999) · Journal of Surgical Research · doi:10.1006/jsre.1998.5511 · Cited by 71
Taketo, M. M. (1998) · Inflammation Research · doi:10.1007/s000110050295 · Cited by 71
Herrmann, J. L., Menter, D. G., Beham, A. W., von Eschenbach, A., & McDonnell, T. J. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3653 · Cited by 44
Fischer, S. M. (1997) · Frontiers in bioscience · doi:10.2741/a207 · Cited by 43
Lavie, Y., & Agranoff, B. W. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67031245.x · Cited by 7
Cited by
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Surh, Y.-J., Chun, K.-S., Cha, H.-H., Han, S. S., Keum, Y.-S., Park, K.-K., & Lee, S. S. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00183-x · Cited by 1,620
Rao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Primary Prevention of Colorectal Cancer
Chan, A. T., & Giovannucci, E. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.057 · Cited by 723
Metadata
- Authors
- Hsu, A.-L., Ching, T.-T., Wang, D.-S., Song, X., Rangnekar, V. M., & Chen, C.-S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-04
- Volume
- 275
- Issue
- 15
- Pages
- 11397-11403
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1998394615
- Cited by
- 671
- References
- 42
- FWCI
- 31.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.